A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors

Study Summary

Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.

Interventions

Study Locations

Facility	City	State	Country
Tianjin Medical University Cancer Institute and Hospital	Tianjin		China

Official Trial Information

View on ClinicalTrials.gov